Key Highlights

  • Summit Therapeutics shares are trading at $16.43 in Wednesday's session, down 4.03%.
  • The pullback gives back part of a sharp rally sparked by updated ivonescimab survival data from the HARMONi and Harmoni-6 trials.
  • Investors are reassessing valuation after the stock's outsized run this year, even as the ESMO 2026 Presidential Symposium is set to showcase new data on the drug.
  • The broader healthcare sector ETF traded roughly flat, suggesting the move is company-specific rather than sector-wide.

Shares Pull Back After a Sharp Rally on Trial Data

Summit Therapeutics (NASDAQ:SMMT) shares are pulling back sharply in Wednesday's session, giving back part of the rally sparked by updated ivonescimab survival data from the HARMONi and Harmoni-6 datasets in lung and biliary tract cancers. That data had fueled speculation about the drug's potential challenge to Merck's Keytruda in non-small cell lung cancer, and today's decline reflects investors reassessing valuation after the sharp move higher rather than any new negative development.

A Clinical-Stage Oncology Company Built Around Ivonescimab

Summit Therapeutics is a clinical-stage biopharmaceutical oncology company headquartered in Miami, Florida, with additional offices in Menlo Park, California, and Oxford, UK, focused on discovering, developing and commercializing therapies that address serious unmet medical needs. Its lead pipeline asset is ivonescimab, a novel bispecific antibody targeting both PD-1 and VEGF, in-licensed from China's Akeso, currently being evaluated in global Phase III trials for non-small cell lung cancer and colorectal cancer, and already approved by China's NMPA in combination with chemotherapy for certain NSCLC indications.

ESMO Presidential Symposium Looms as Next Catalyst

The stock had rallied roughly 23% over the prior 90 days and more than doubled year-to-date into the recent data readout, meaning today's pullback looks like profit-taking after the anticipated catalyst was already priced in, even though analysts' average price target still implies the shares are undervalued. Investors are also looking ahead to the ESMO 2026 Presidential Symposium, set to showcase new HARMONi-GI1 data on ivonescimab plus chemotherapy versus Durvalumab plus chemotherapy in advanced biliary tract cancer, keeping clinical catalysts in focus even as the broader healthcare and biotech trading tone remains mixed.